Perspective · 2 Feb 2024
Conference abstractPublished 1 Oct 2012
Developing cell therapy products for commercial use
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
D eveloping a cell therapy product for commercial use is a novel and complicated process. Determining the appropriate infrastructure for each stage of product development and testing can be crucial to taking the product to the clinic. Establishing appropriate timelines and meeting budgets demands can be a challenge for start-up companies with limited funding. This session will discuss the Bioheart experience in taking cell therapy products to the clinic and the challenges to ensure patient safety and financial security in the path the commercialization. Autologous immature myoblasts form new contractile muscle in myocardial scar tissue. Over 2000 animal studies have demonstrated both safety and efficacy. Over 400 patients have enrolled in myoblast transplantation for heart repair clinical trials since June of 2000. Catheter delivery studies began in May of 2001. 94% of treated patients have improved in heart failure class while only 6% have worsened. 84% of treated patients exhibited improvements in measurable parameters such as exercise capacity testing while only 16% have worsened. LVEF at exercise measured by dobutamine stress echo has shown cell treated patients with 15% improvement. Phase II/III randomized double blinded placebo controlled studies are on-going. Interim results were shared demonstrating that cell treated patients improved 91.7 meters in exercise capacity testing while placebo patients on optimal CHF drugs declined 4 meters. Results from 23 years of animal studies and 11 years of clinical studies demonstrate efficacy with reasonable safety.
Subjects
BiologyAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Similar by topic
Conference abstract · 25 Mar 2019
Stem Cell Therapy – A 10 year Clinical Experience with advanced products reducing healing time and bettering medical and surgical outcome
Review article · 12 Feb 2014
General Requirement for Quality and Safety in Stem Cell and Cell-Based Products for Translational Therapy
Opinion · 2 Feb 2024
Challenges and Development of T-Cell Therapy in Preventing Liver Immunity and Cancer
Opinion · 4 Nov 2022
Development of Transplantable Beta Cells for Cell Therapy using Patient- Specific Cells
More from this journal
The newest in Journal of Cell Science & Therapy.
Perspective · 2 Feb 2026
Exploring Senescence and Its Influence on Tissue Function and Therapeutic Research
Commentary · 2 Feb 2026
Metabolism Regulation and Its Influence on Therapeutic Development in Human Disease
Commentary · 2 Dec 2025
Cellular Membranes and Transport Proteins as Regulators of Homeostasis and Metabolic Coordination
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Cell Science & Therapy
- SubjectBiology
- BylineArticles whose byline prints “Kristin Comella”

